$LGVN News
Last published 2w ago
- 2w agoLGVNLGVNRLongeveron Announces Engagement of Lucid Capital MarketsGlobeNewswireMIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the "Company") (NASDAQ:LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore
- 2w agoLGVNLGVNRLongeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewswireELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions As previously reported, the ELPIS II trial did not meet the
- 1mo agoLGVNLGVNRLongeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewswireCompany Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction
- 2mo agoLGVNLGVNRLongeveron to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related
- 2mo agoLGVNLGVNRLongeveron Announces 1-for-10 Reverse Stock SplitGlobeNewswireMIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 2mo agoLGVNLGVNRIRDDERMLongeveron Appoints Nirav Jhaveri as Chief Financial OfficerGlobeNewswireMr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE)
- 3mo agoLGVNLongeveron 2026 Q2 Financial Results and Business Update Call - LONGEVERON INCEarnings Call TranscriptsGood day and welcome to the Longueveron 2026 Second Quarter Financial Results Conference Call. If you would like to ask a question today, please press star 1 on your telephone keypad. A confirmation tone will indicate yo
- 3mo agoLGVNLGVNRLongeveron Announces 2026 Second Quarter Financial Results and Provides Business UpdateGlobeNewswireOn track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and
- 3mo agoLGVNLGVNRLongeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global CompetitionGlobeNewswireLongeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, Aug. 11, 2026
- 3mo agoLGVNLGVNRLongeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026GlobeNewswireMIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related
- 3mo agoLGVNLGVNRDeborah D. Ascheim, M.D. Elected to Longeveron Board of DirectorsGlobeNewswireMIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 4mo agoLGVNLGVNRLongeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s DiseaseGlobeNewswirePoster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled "Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed
- 4mo agoLGVNLGVNRLongeveron® Appoints Marie Washburn as Chief Financial OfficerGlobeNewswireMs. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy
- 4mo agoLGVNNew Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)GlobeNewswireMIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 5mo agoLGVNLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)GlobeNewswireMIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 5mo agoLGVNLongeveron to Present at BIO International Convention 2026GlobeNewswireCompany will highlight new and recently published data for stem cell therapy laromsestrocel Focus on potential partnership and strategic opportunities for Hypoplastic Left Heart Syndrome, Alzheimer's disease, Pediatric
- 5mo agoLGVNLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key PrioritiesGlobeNewswireMIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today
- 6mo agoLGVNLongeveron 2026 Q1 Financial Results and Business Update CallLONGEVERON INCEarnings Call TranscriptsLadies and gentlemen, greetings and welcome to the Longevron 2026 First Quarter Financial Results and Business Update Call. At this time, all participants are in listen-only mode. A brief question and answer session will
- 6mo agoLGVNLongeveron Announces 2026 First Quarter Financial Results and Provides Business UpdateGlobeNewswireOn track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and
- 6mo agoLGVNLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)GlobeNewswirePhase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationDMC performed a risk-benefit assessment, identified no new
- 6mo agoLGVNLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewswireMIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related
- 6mo agoLGVNLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026GlobeNewswireMIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today
- 6mo agoAVAILGVNLLYNVO+1The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialGlobeNewswireIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX),
- 7mo agoLCTXOCGNVRTXLGVNBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsPR NewswireFor most of modern biology, aging has been treated as a backdrop — the inevitable canvas on which individual diseases are painted. That is beginning...
- 7mo agoLGVNLongeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)GlobeNewswireThe patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic
- 7mo agoMESOLGVNLCTXMNKDA Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.PR NewswireEquity-Insider.com — There is a key "master" protein in your body called α-Klotho. You've probably never heard of it. But the scientific community...
- 8mo agoLGVNLongeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026GlobeNewswireMIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 8mo agoLGVNLongeveron Announces Private Placement of up to $30 MillionGlobeNewswire$15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules
- 8mo agoFBLGFATEMESOLGVNCell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThemPR NewswireUSANewsGroup.com News Commentary — The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical...
- 8mo agoLGVNLongeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem CellGlobeNewswireMIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related
- 9mo agoLGVNLongeveron® Appoints Stephen H. Willard as Chief Executive OfficerGlobeNewswireMr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and
- 9mo agoLGVNLongeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher ProgramGlobeNewswireThe Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority
- 9mo agoLGVNLongeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)GlobeNewswireThe patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic
- 9mo agoLGVNLongeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewswireELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are
- 10mo agoLGVNLongeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026GlobeNewswireMission-aligned community focused on accelerating breakthroughs in Alzheimer's disease, Parkinson's disease and related conditionsSupported by Health Moonshot Champions, including the Alzheimer's Drug Discovery
- 10mo agoLGVNLongeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell TherapyGlobeNewswireThe patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of
- 11mo agoLGVNLongeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) ForumGlobeNewswireMIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related
- 11mo agoLGVNLongeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with InflammagingGlobeNewswireThe patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients
- 11mo agoLGVNLongeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)GlobeNewswireResults obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to
- 11mo agoLGVNLongeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)GlobeNewswireMIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,
- 12mo agoLGVNLongeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell TherapyGlobeNewswireThe patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved treatments for
- 1y agoLGVNLongeveron® Announces Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireOn track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and
- 1y agoLGVNLongeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025GlobeNewswireMIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,
- 1y agoLGVNLongeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart DefectGlobeNewswireLaromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II)
- 1y agoLGVNLongeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities ConferenceGlobeNewswireMIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,
- 1y agoLGVNGeorge Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of DirectorsGlobeNewswireMIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,
- 1y agoLGVNLongeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the MesaGlobeNewswireExploring potential partnerships and strategic opportunities for the Company's stem cell therapy program in Alzheimer's diseaseAlzheimer's disease development program with positive data in successful Phase 1 and Phase 2a
- 1y agoLGVNLongeveron® Announces Key Leadership UpdatesGlobeNewswireThan Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa'el Hashad to step
- 1y agoLGVNLongeveron® to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireMIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic
- 1y agoLGVNLongeveron Inc. (LGVN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts